We are live on ! Find out more
OKUR

OnKure Therapeutics

68 hedge funds and large institutions have $40.6M invested in OnKure Therapeutics in 2023 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 17 increasing their positions, 16 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

197% more call options, than puts

Call options by funds: $3.38M | Put options by funds: $1.14M

59% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 17

17% more funds holding

Funds holding: 5868 (+10)

6% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 16

0.47% less ownership

Funds ownership: 8.09%7.63% (-0.47%)

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

80% less capital invested

Capital invested by funds: $208M → $40.6M (-$168M)

Holders
68
Holders Change
+10
Holders Change %
+17.24%
% of All Funds
0.99%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.01%
New
27
Increased
17
Reduced
16
Closed
17
Calls
$3.38M
Puts
$1.14M
Net Calls
+$2.24M
Net Calls Change
+$2.25M

OKUR Hedge Fund Activity: Q4 2023 in Review

68 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in OnKure Therapeutics (OKUR) for Q4 2023, worth a combined $40.6M — down 80% from $208M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new OKUR positions and 17 closed out — a net gain of 10 holders — while 17 added to existing stakes and 16 trimmed.

The largest buyer was Tang Capital Management, opening a new position worth an estimated $20.8M. The largest seller was Novo Holdings A/S, exiting entirely with an estimated $25.3M sold.

  • 68 institutional investors held OnKure Therapeutics (OKUR) as of Q4 2023, up from 58 in Q3 2023.
  • Funds reported $40.6M of OnKure Therapeutics stock for Q4 2023, down 80% quarter-over-quarter.
  • 27 funds opened new OnKure Therapeutics positions in Q4 2023 and 17 closed out, a net change of +10 holders.
  • The largest OnKure Therapeutics buyer in Q4 2023 was Tang Capital Management, an estimated $20.8M added.
  • The largest OnKure Therapeutics seller in Q4 2023 was Novo Holdings A/S, an estimated $25.3M sold.

Based on aggregated 13F filings for Q4 2023.